Patent US3967243A successfully refreshed from Google Patents.
Patent US5096705A successfully refreshed from Google Patents.
US5096705A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Human immune interferon
Assignee: Genentech Inc
•
Filing: 1990-07-31
•
Granted: 1992-03-17
•
Expires: 2010-07-31
Abstract
Abstract Disclosed is a complete description of the preparation of novel, recombinant human immune interferon and des-CYS-TYR-CYS recombinant human immune interferon via recombinant DNA techniques utilizing any of an assortment of expression vectors and host cultures. The human immune (gamma) interferon (IFN- gamma ), is isolated and characterized in terms of DNA and amino acid sequences, physical attributes and biological activity.
Inventors
- 👤 David V. Goeddel
- 👤 Patrick W. Gray
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 04:58
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/80; C12N15/81; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/555; C07K14/57; C12N15/70; C12N15/71; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
11 words
A recombinant human immune interferon having the amino acid sequence: ##STR3##
Claim 2
Dependent Claim
11 words
A recombinant human immune interferon having the amino acid sequence: ##STR3##
Claim 3
Dependent Claim
26 words
The human immune interferon according to claim 1 additionally comprising the amino acid methionine attached to the N-terminus of the amino-terminal amino acid of said interferon.
Claim 4
Dependent Claim
25 words
The human immune interferon according to claim 1 additionally comprising a cleavable conjugate attached to the N-terminus of the amino-terminal amino acid of said interferon.
Claim 5
Dependent Claim
8 words
Glycosylated human immune interferon according to claim 1.
Claim 6
Dependent Claim
41 words
A pharmaceutical composition useful for treating a subject requiring antitumor or antiviral treatment or suffering from an immunosuppressive condition comprising a therapeutically effective amount of a human immune interferon according to claim 1 in admixture with a pharmaceutically acceptable carrier vehicle.
Claim 7
Dependent Claim
36 words
A method of treating a subject requiring antitumor or antiviral treatment or suffering from an immunosuppressive condition which method comprises administering to such subject a therapeutically effective amount of human immune interferon according to claim 1.
Claim 8
Dependent Claim
8 words
Unglycosylated human immune interferon according to claim 1.
References Cited (Backward Citations)
US4285929A
Cited
US4382027A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-03-17 | 1995-09-16 | 1996-03-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-03-17 | 1999-09-16 | 2000-03-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-03-17 | 2003-09-16 | 2004-03-17 | $7700.00 | Window Closed / Lapsed |